Enpatoran

DB16501InvestigationalSmall molecule

Enpatoran (M5049) was under investigation in clinical trials for various conditions. It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in... Additionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis (NCT05650567).

Mechanism: M5049 is a small molecule Toll-like receptor (TLR)7 and TLR8 inhibitor. The drug blocks activation of TLR7/8, thereby stopping immune cell activation, inflammation, and the progression into a cyotkine storm. The drug is currently being investigated against COVID-19.
Curator reviewed
Formula / weight: C₁₆H₁₅F₃N₄ · 320.319 g/mol (avg)
Also known as: 5-((3R,5S)-3-AMINO-5-TRIFLUOROMETHYLPIPERIDIN-1-YL)QUINOLINE-8-CARBONITRILE
Code names: M-5049

Resolves to

Compound

UNII7CZ390V26XCAS2101938-42-3ChEMBLCHEMBL4802159

Structure

InChIKeyBJXYHBKEQFQVES-NWDGAFQWSA-NSMILESN[C@@H]1C[C@@H](CN(C1)C1=CC=C(C#N)C2=C1C=CC=N2)C(F)(F)F

Targets

Q9NYK1TLR7Q9NR97TLR8

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enpatoran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account